Added to YB: 2026-04-22
Pitch date: 2026-04-20
SYRE [neutral]
Spyre Therapeutics, Inc.
-2.89%
current return
Author Info
No bio for this author
Company Info
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Market Cap
$6.3B
Pitch Price
$73.39
Price Target
120.00 (+64%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-36.96
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Monthly Core Conviction #1: SYRE and The Full M&A Book
SYRE (update): Extended half-life biologics platform w/ SPY001 Phase 2 validated (9.2pt RHI reduction, 40% remission, 90+ day half-life). 4 POC readouts mid-H2 2026: SPY002/003 UC, SPY072 RA/PsA/axSpA. $783M cash thru readouts. M&A thesis builds late 2026/early 2027. Max position, $100-120 PT (+37-64% from $73) on platform de-risking.
Read full article (1 min)